Treatment of Swedish Patients with Graves' Hyperthyroidism Is Associated with Changes in Acylcarnitine Levels

Al-Majdoub, Mahmoud; Lantz, Mikael; Sartipy, Peter

doi:10.1089/thy.2017.0218

Cited by 18 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most prominent small-molecule signature characterizing the restoration of euthyroidism after treatment for Graves' disease is a decline in plasma AC levels (Chng et al 2016, Al-Majdoub et al 2017, which is well in line with observations from population-based studies (Jourdan et al 2014, Lange et al 2018). Yet, the quantitative impact of TH on the blood AC profile remains to be established, since observations in a small cohort (N = 12) of hypothyroid and hyperthyroid did not support strong departures in plasma AC levels from healthy controls (Wong et al 2013).…”

Section: Graves' Diseasesupporting

confidence: 74%

“…Yet, the quantitative impact of TH on the blood AC profile remains to be established, since observations in a small cohort (N = 12) of hypothyroid and hyperthyroid did not support strong departures in plasma AC levels from healthy controls (Wong et al 2013). However, the studies done by Chng et al (2016)) and Al-Majdoub et al (2017) confirmed previous observations with respect to phenylalanine, tyrosine as well as TCA cycle intermediates. In general, successful restoration of euthyroidism is characterized by a less pronounced utilization of FAs for energy demands.…”

Section: Graves' Diseasementioning

confidence: 56%

“…The observations are in good agreement with the ubiquitous impact of TH on metabolic processes. Equivalent studies in humans (Chng et al 2016, Al-Majdoub et al 2017 highlighted the tremendous potential of metabolomics to improve our understanding of thyroid disorders, in particular, TH excess and even further the usefulness to complement diagnosis of thyroid disorders.…”

Section: Thyroid Disorders and Modelsmentioning

confidence: 99%

See 2 more Smart Citations

Empowering thyroid hormone research in human subjects using OMICs technologies

Pietzner

Kacprowski

Friedrich

2018

Journal of Endocrinology

View full text Add to dashboard Cite

OMICs subsume different physiological layers including the genome, transcriptome, proteome and metabolome. Recent advances in analytical techniques allow for the exhaustive determination of biomolecules in all OMICs levels from less invasive human specimens such as blood and urine. Investigating OMICs in deeply characterized population-based or experimental studies has led to seminal improvement of our understanding of genetic determinants of thyroid function, identified putative thyroid hormone target genes and thyroid hormone-induced shifts in the plasma protein and metabolite content. Consequently, plasma biomolecules have been suggested as surrogates of tissue-specific action of thyroid hormones. This review provides a brief introduction to OMICs in thyroid research with a particular focus on metabolomics studies in humans elucidating the important role of thyroid hormones for whole body metabolism in adults.

show abstract

Section: Graves' Diseasesupporting

confidence: 74%

Section: Graves' Diseasementioning

confidence: 56%

Section: Thyroid Disorders and Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Empowering thyroid hormone research in human subjects using OMICs technologies

Pietzner

Kacprowski

Friedrich

2018

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Based on this observational, secondary analysis of blood samples, we did not find any metabolomic markers that could separate aforementioned thyroid disorders. This is in contrast to other reports showing distinct metabolic profiles between hyperthyroid patients and euthyroid controls on one hand and hyperthyroid patients rendered euthyroid with antithyroid drugs treatment on the other [8][9][10]. One of these publications revealed that during ATD treatment of GD patients over the first 9 months short-chain acylcarnitines increased, whereas intermediate-chain acylcarnitines decreased, and long-chain acylcarnitines remained stable [8].…”

Section: Discussionmentioning

confidence: 59%

“…Some reports have already mapped the metabolic differences of hyperthyroid disorders, especially GD, compared to the metabolome after treatment [8][9][10]. Another study demonstrated alterations of the metabolome in patients with nodular goiters compared to controls [11].…”

Section: Introductionmentioning

confidence: 99%

Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study

et al. 2019

View full text Add to dashboard Cite

Early diagnosis of thyroid disorders is key to further treatment. We assessed the ability of a high-throughput proton NMR metabolomic profile to distinguish disease type amongst of Graves’ disease (n=87), Hashimoto’s thyroiditis (n=17), toxic goiter (n=11), and autoimmune thyroiditis [i. e., subacute thyroiditis (n=4), postpartum thyroiditis (n=1)]. This observational study was conducted investigating patients presenting with a thyroid disorder at a Swiss hospital endocrine referral center and an associated endocrine outpatient clinic. The main outcome was diagnosis of thyroid disorder based on classical parameters. Blood draws took place as close as possible to treatment initiation. We performed one-way ANOVA and partial least squares discriminant analysis (PLS-DA) as multivariate classification and feature ranking method. One-way ANOVA analysis yielded following significantly different metabolites, triglycerides in small VLDL, triglycerides in very small VLDL, and triglycerides in large LDL (FDR=0.04). There was no distinct separation of any of the 4 diagnoses by PLS-DA. We did not find a metabolomic biomarker combination capable of predicting diagnosis. Preanalytical issues might have influenced our results. We strongly suggest replicating our work in another cohort.

show abstract

Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease

Setoyama

Lee

Moon

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Thyroid hormone excess induces protein energy wasting, which in turn promotes muscle weakness and bone loss in patients with Graves' disease. Although most studies have confirmed a relationship between thyrotoxicosis and muscle dysfunction, few have measured changes in plasma metabolites and immune cells during the development and recovery from thyrotoxic myopathy. The aim of this study was to identify specific plasma metabolites and T-cell subsets that predict thyrotoxic myopathy recovery in patients with Graves' disease. Methods One hundred patients (mean age, 40.0 ± 14.2 years; 67.0% female), with newly diagnosed or relapsed Graves' disease were enrolled at the start of methimazole treatment. Handgrip strength and Five Times Sit to Stand Test performance time were measured at Weeks 0, 12, and 24. In an additional 35 patients (mean age, 38.9 ± 13.5 years; 65.7% female), plasma metabolites and immunophenotypes of peripheral blood were evaluated at Weeks 0 and 12, and the results of a short physical performance battery assessment were recorded at the same time. ResultsIn both patient groups, methimazole-induced euthyroidism was associated with improved handgrip strength and lower limb muscle function at 12 weeks. Elevated plasma metabolites including acylcarnitines were restored to normal levels at Week 12 regardless of gender, body mass index, or age (P trend <0.01). Senescent CD8 + CD28 À CD57 + Tcell levels in peripheral blood were positively correlated with acylcarnitine levels (P < 0.05) and decreased during thyrotoxicosis recovery (P < 0.05). High levels of senescent CD8 + T cells at Week 0 were significantly associated with small increases in handgrip strength after 12 weeks of methimazole treatment (P < 0.05), but not statistically associated with Five Times Sit to Stand Test performance. Conclusions Restoring euthyroidism in Graves' disease patients was associated with improved skeletal muscle function and performance, while thyroid hormone-associated changes in plasma acylcarnitines levels correlated with muscle dysfunction recovery. T-cell senescence-related systemic inflammation correlated with plasma acylcarnitine levels and was also associated with small increases in handgrip strength.

show abstract

Treatment of Swedish Patients with Graves' Hyperthyroidism Is Associated with Changes in Acylcarnitine Levels

Abstract: GD and treatment of the disease is associated with pronounced acyl chain length-dependent alterations in acylcarnitine levels. These changes may be impacted by ethnicity and or dietary differences.

Cited by 18 publications

References 42 publications

Empowering thyroid hormone research in human subjects using OMICs technologies

Empowering thyroid hormone research in human subjects using OMICs technologies

Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study

Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease

Contact Info

Product

Resources

About